2023年2月第30卷第2期贝伐珠单抗与奥希替尼联合治疗肺腺癌的效果及对患者近期生存质量的影响郑铁桩，石琳琳（河南省洛阳市嵩县中医院肿瘤三病区，河南洛阳471401）【摘要】目的探讨贝伐珠单抗与奥希替尼联合治疗肺腺癌的效果及对患者近期生存质量的影响。方法80例肺腺癌患者分为两组各40例，对照组给予奥希替尼治疗，观察组给予贝伐珠单抗与奥希替尼联合治疗，比较两组的疗效、不良反应及生活质量。结果治疗后，两组的ORR比较，差异无统计学意义（P＞0.05）；观察组的DCR显著高于对照组（P＜0.05）。两组治疗期间的Ⅰ～Ⅱ级和Ⅲ~Ⅳ级不良反应发生率比较，差异均无统计学意义（P＞0.05）。治疗后，观察组的生活质量改善率显著高于对照组（P＜0.05）。结论贝伐珠单抗与奥希替尼联合治疗肺腺癌的效果显著，有助于控制病情进展，改善患者近期生活质量。【关键词】贝伐珠单抗；奥希替尼；肺腺癌；疗效；生活质量中图分类号：R734.2文献标识码：Adoi:10.3969/j.issn.1674-4659.2023.02.0173EffectofBevacizumabMonoclonalAntibodyCombinedwithOsimertinibintheTreatmentofLungAdenocarcinomaandItsImpactontheRecentQualityofLifeofPatients//ZHENGTiezhuang,SHILinlin(3rdWardofTumor,SongxianCountyHospitalofTraditionalChineseMedicine,Luoyang471401,China)[Abstract]ObjectiveToexploretheeffectofbevacizumabmonoclonalantibodycombinedwithosimertinibinthetreatmentoflungadenocarcinomaanditsimpactontherecentqualityoflifeofpatients.Methods80patientswithlungadenocarcinomaweredividedintotwogroups.Thecontrolgroupwastreatedwithosimertinib,andtheobservationgroupwastreatedwithbevacizumabmonoclonalantibodycombinedwithosimertinib.Theefficacy,adversereactionsandqualityoflifewerecomparedbetweenthetwogroups.ResultsAftertreatment,nosignificantdifferencewasfoundinORRbetweenthetwogroups(P>0.05);TheDCRoftheobservationgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).NosignificantdifferencewasfoundintheincidencesofⅠ～ⅡandgradeⅢ~Ⅳadversereactionsbetweenthetwogroupsduringtreatment(P>0.05).Aftertreatment,theimprovementrateofqualityoflifeoftheobservationgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).ConclusionsBevacizumabmonoclonalantibodycombinedwithosimertin...
